Program
puxitatug samrotecan
Also written as “AZD8205”, “AZD8205 in combination with AZD9574” and “Puxitatug Samrotecan”.
Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms, led by AstraZeneca.
Furthest: phase 3, since Jun 23, 20252 company-led studies, 2 open or runningNext primary completion: Sep 29, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 22 open or running | phase 3since Jun 23, 2025 | Oct 13, 2021 | Sep 29, 2027phase 2 · NCT05123482 |
- Named in AstraZeneca’s own pipeline as
puxitatug samrotecan
, phase 3, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2021First study: phase 2 study in Breast NeoplasmsFirst studyNCT05123482 · 460 planned · United States, Australia, Belgium and more
- Jun 23, 2025Phase 3 study in Endometrial NeoplasmsNCT07044336 · 800 planned · United States, Argentina, Australia and more
Ahead
- Sep 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05123482
- Oct 15, 2027Primary completion: phase 3 study in Endometrial NeoplasmsNCT07044336
TargetBeta
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) linked to samrotecan, which is coposed of a linker and the topoisomerase-1 inhibitor (TOP1i; TOP-Ii) exatecan, with potential antineo…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) ”NCIt, by rule
Other programs on VTCN1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mocertatug rezetecan | GlaxoSmithKline | phase 3 | 11 |
| Anti-B7-H4 Antibody Drug Conjugate BG-C9074rule | BeOne Medicines | phase 3 | 2 |
| Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103rule | abl-bio-inc | phase 2 | 2 |
| Anti-B7-H4/MMAE ADC LNCB74rule | ligachem-biosciences-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07044336Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Oct 15, 2027 | 800 |
| NCT05123482Breast Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Sep 29, 2027 | 460 |
How it is read
Names in the registry
- “AZD8205”, 1 entry
- “AZD8205 in combination with AZD9574”, 1 entry
- “Puxitatug Samrotecan”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.